Description

Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells[1].–Applications-Cancer-Kinase/protease-Formula-C21H18FN5O-Citation–References-[1]Guan J, et al. Chemical reprogramming of human somatic cells to pluripotent stem cells. Nature. 2022 May;605(7909):325-331. -CASNumber-796967-16-3-MolecularWeight-375.40-Compound Purity–SMILES-O=C(NC1=CC=C(C2=C3C(N)=NNC3=CC=C2)C=C1)NC4=C(C=CC(C)=C4)F-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-PDGFR;VEGFR-Isoform–Pathway-Protein Tyrosine Kinase/RTK-MCE Product type-GMP Small Molecules